

Spectrum Physician's Orders Health DARBEPOETIN (ARANESP) ADULT, OUTPATIENT, INFUSION CENTER

Page 1 to 2

Patient Name
DOB
MRN
Physician
FIN

☐ Interval: Every☐ Interval: Every☐ Interval: Every	v 14 days v 28 days	fied below:						
□ Interval: Every Duration: □ Until date: □ 1 year □# of Tr								
Anticipated Infusio	n Date	ICD 10 Code with D	Description					
Height	(cm) Weight	(kg) Allergies	s					
Provider Specialty ☐ Allergy/Immuno ☐ Cardiology ☐ Gastroenterolog ☐ Genetics Site of Service	logy □ Infection □ Internal	••	□ OB/GYN □ Other □ Otolaryngology □ Pulmonary	□ Rheumatology□ Surgery□ Urology□ Wound Care				
☐ SH Gerber ☐ SH Helen DeVo		nmen Holton (GR) ington	☐ SH Pennock ☐ SH Reed City	☐ SH United Memorial ☐ SH Zeeland				
Appointment Reques	sts							
Infusion Ap								
Provider Ordering Gu	uidelines							
	VIDER REMINDER ETIN (ARANESP):	15						
serum ferriti	Evaluate iron status in all patients before and during treatment. The manufacturer recommends supplemental iron be administered if serum ferritin is less than 100 ng/mL or serum transferrin saturation (TSAT) is less than 20%. Most patients with CKD will require iron supplementation.							
Erythropoiesis-stimulating agents (ESAs) increased the risk of serious cardiovascular events, myocardial infarction, stroke, venous thromboembolism, vascular access thrombosis, and mortality in clinical studies when administered to target hemoglobin levels greater than 11 g/dL (and provide no additional benefit); a rapid rise in hemoglobin (greater than 1 g/dL over 2 weeks) may also contribute to these risks. To decrease these risks, and risk of cardio- and thrombovascular events, use the lowest dose needed to avoid red blood cell transfusions.								
Blood press	ure should be monitored	closely during therapy.						
Nursing Orders								

ONC NURSING COMMUNICATION 107 DARBEPOETIN (ARANESP):

An FDA-approved patient medication guide, which is available with the product information and at https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103951s5375lbl.pdf#page=25, must be dispensed with this medication.

Spectrum Darbepoetin (Aranesp) -ADULT, OUTPATIENT **INFU** (CON

ADULI, OUTPATIENT,	I ME
INFUSION CENTER	
(CONTINUED)	Ph
Page 2 to 2	FII

Patient	Name
DOB	

vsician

- 1	
+	

ı	L	а	b	S

Hemoglobin + Hematocrit (H+H) Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Collect, Blood, Blood, Venous

Labs - Monthly

		Interval	Duration		
✓	Ferritin, Blood Level	Every 28 days	Until discontinued		
Status: Future, Expected: S, Expires: S+184, URGENT, Clinic Collect, Blood, Blood, Venous					
~	Transferrin, Blood Level	Every 28 days	Until discontinued		
Status: Future, Expected: S, Expires: S+365, URGENT, Clinic Collect, Blood, Blood, Venous					
~	Iron and Iron Binding Capacity Level	Every 28 days	Until discontinued		
Status: Future, Expected: S, Expires: S+184, URGENT, Clinic Collect, Blood, Blood, Venous					

Treatment Parameters

ONC MONITORING AND HOLD PARAMETERS 2 Notify provider if Hemoglobin is greater than 11 g/dL OR Hematocrit is greater than 30%

Medications

darbepoetin alfa (ARANESP) injection

Subcutaneous, Once, Starting S, For 1 Doses Dose:

25 mcg

40 mcg

□ 60 mcg

□ 100 mcg 200 mcg

□ 300 mcg

Indications:

□ Anemia

☐ ESRD on Dialysis

☐ Chemotherapy-Induced Anemia

☐ Radiation Therapy Toxicity

Monitor blood pressure closely during therapy.

Telephone order/Verbal order documented and read-back completed. Practitioner's initials _

NOTE: Unless Order is written DAW (dispense as written), medication may be supplied which is a generic equivalent by nonproprietary name.

TRANSCRIBED:		VALIDATED:		ORDERED:		
TIME	DATE	TIME	DATE	TIME	DATE	Pager #
	Sign		R.N. Sign		Physician Print	Physician